These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

882 related items for PubMed ID: 22351686

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Evaluating melanoma drug response and therapeutic escape with quantitative proteomics.
    Rebecca VW, Wood E, Fedorenko IV, Paraiso KH, Haarberg HE, Chen Y, Xiang Y, Sarnaik A, Gibney GT, Sondak VK, Koomen JM, Smalley KS.
    Mol Cell Proteomics; 2014 Jul; 13(7):1844-54. PubMed ID: 24760959
    [Abstract] [Full Text] [Related]

  • 4. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.
    Phadke MS, Sini P, Smalley KS.
    Mol Cancer Ther; 2015 Jun; 14(6):1354-64. PubMed ID: 25873592
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. FoxO proteins' nuclear retention and BH3-only protein Bim induction evoke mitochondrial dysfunction-mediated apoptosis in berberine-treated HepG2 cells.
    Shukla S, Rizvi F, Raisuddin S, Kakkar P.
    Free Radic Biol Med; 2014 Nov; 76():185-99. PubMed ID: 25128467
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M, Aust MM, Attkisson E, Williams DC, Ferreira-Gonzalez A, Grant S.
    Cancer Res; 2013 Feb 15; 73(4):1340-51. PubMed ID: 23243017
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
    Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G.
    Eur J Cancer; 2016 Mar 15; 55():98-110. PubMed ID: 26790143
    [Abstract] [Full Text] [Related]

  • 17. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM, Frederick DT, Sullivan RJ, Flaherty KT, Srivastava SK.
    Oncotarget; 2015 Dec 01; 6(38):40535-56. PubMed ID: 26497853
    [Abstract] [Full Text] [Related]

  • 18. HI-511 overcomes melanoma drug resistance via targeting AURKB and BRAF V600E.
    Chang X, Zhang T, Wang Q, Rathore MG, Reddy K, Chen H, Shin SH, Ma WY, Bode AM, Dong Z.
    Theranostics; 2020 Dec 01; 10(21):9721-9740. PubMed ID: 32863956
    [Abstract] [Full Text] [Related]

  • 19. Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas?
    Catalanotti F, Solit DB.
    Clin Cancer Res; 2012 May 01; 18(9):2420-2. PubMed ID: 22442059
    [Abstract] [Full Text] [Related]

  • 20. Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF V600E-Mutant Melanoma.
    Eroglu Z, Chen YA, Gibney GT, Weber JS, Kudchadkar RR, Khushalani NI, Markowitz J, Brohl AS, Tetteh LF, Ramadan H, Arnone G, Li J, Zhao X, Sharma R, Darville LNF, Fang B, Smalley I, Messina JL, Koomen JM, Sondak VK, Smalley KSM.
    Clin Cancer Res; 2018 Nov 15; 24(22):5516-5524. PubMed ID: 29674508
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.